Design and characterization of ebolavirus GP prehairpin intermediate mimics as drug targets
暂无分享,去创建一个
J. Dye | A. Herbert | C. Hill | D. Eckert | F. Whitby | Matthew T. Weinstock | Tracy R Clinton | Matthew T Weinstock | Michael T Jacobsen | Nicolas Szabo-Fresnais | Maya J Pandya | Frank G Whitby | Andrew S Herbert | Laura I Prugar | Rena McKinnon | Christopher P Hill | Brett D Welch | John M Dye | Debra M Eckert | Michael S Kay | Brett D. Welch | M. Kay | Michael T. Jacobsen | Laura I. Prugar | Nicolas Szabo‐Fresnais | Rena Mckinnon | Tracy R. Clinton | Maya J. Pandya | C. Hill
[1] B. Autran,et al. Bioterrorism: management of major biological agents. , 2006, Cellular and molecular life sciences : CMLS.
[2] Matthew T. Weinstock,et al. Protease‐resistant peptide design—empowering nature's fragile warriors against HIV , 2012, Biopolymers.
[3] H. Feldmann,et al. Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections. , 2011, Journal of bioterrorism & biodefense.
[4] R. Connor,et al. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. , 1995, Virology.
[5] J. Dye,et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1 , 2011, Nature.
[6] P. S. Kim,et al. Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[7] Vincent B. Chen,et al. Correspondence e-mail: , 2000 .
[8] I. Brooks,et al. Determination of rate and equilibrium binding constants for macromolecular interactions using surface plasmon resonance: use of nonlinear least squares analysis methods. , 1993, Analytical biochemistry.
[9] H. Feldmann,et al. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[10] W. Weissenhorn,et al. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. , 1998, Molecular cell.
[11] C. Wohlfarth. Partial specific volume of poly(ethylene glycol) , 2010 .
[12] Z. Otwinowski,et al. Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[13] Brian G Fox,et al. A combined approach to improving large-scale production of tobacco etch virus protease. , 2007, Protein expression and purification.
[14] S. Whelan,et al. Endosomal Proteolysis of the Ebola Virus Glycoprotein Is Necessary for Infection , 2005, Science.
[15] R. Ray,et al. Identification of a Small-Molecule Entry Inhibitor for Filoviruses , 2011, Journal of Virology.
[16] P. S. Kim,et al. Inhibiting HIV-1 Entry Discovery of D-Peptide Inhibitors that Target the gp41 Coiled-Coil Pocket , 1999, Cell.
[17] J. Kuhn,et al. Conserved Receptor-binding Domains of Lake Victoria Marburgvirus and Zaire Ebolavirus Bind a Common Receptor* , 2006, Journal of Biological Chemistry.
[18] S. Danishefsky,et al. Free-radical-based, specific desulfurization of cysteine: a powerful advance in the synthesis of polypeptides and glycopolypeptides. , 2007, Angewandte Chemie.
[19] Kathryn L. Schornberg,et al. A new player in the puzzle of filovirus entry , 2012, Nature Reviews Microbiology.
[20] P. Dawson,et al. An efficient Fmoc-SPPS approach for the generation of thioester peptide precursors for use in native chemical ligation. , 2008, Angewandte Chemie.
[21] Stephen C. Peiper,et al. Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.
[22] Lorenz M. Mayr,et al. Identification of d-Peptide Ligands Through Mirror-Image Phage Display , 1996, Science.
[23] Deborah Fass,et al. Core Structure of gp41 from the HIV Envelope Glycoprotein , 1997, Cell.
[24] F. Studier,et al. Protein production by auto-induction in high density shaking cultures. , 2005, Protein expression and purification.
[25] J. Condra,et al. Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41 , 2009, mAbs.
[26] D. Eckert,et al. Design of a modular tetrameric scaffold for the synthesis of membrane-localized D-peptide inhibitors of HIV-1 entry. , 2012, Bioconjugate chemistry.
[27] E. Saphire,et al. Ebolavirus glycoprotein structure and mechanism of entry. , 2009, Future virology.
[28] D O Morgan,et al. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity , 1995, Journal of virology.
[29] T. Matthews,et al. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. , 1993, AIDS research and human retroviruses.
[30] R. Andino,et al. Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses , 1994, Journal of virology.
[31] J. Berg,et al. A comparison of the immunogenicity of a pair of enantiomeric proteins , 1993, Proteins.
[32] J. Berg,et al. A racemic protein , 1992 .
[33] K. Chandran,et al. Inhibition of Ebola Virus Entry by a C-peptide Targeted to Endosomes , 2011, The Journal of Biological Chemistry.
[34] M. Root,et al. HIV-1 gp41 as a target for viral entry inhibition. , 2004, Current pharmaceutical design.
[35] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[36] K. A. Noren,et al. Construction of high-complexity combinatorial phage display peptide libraries. , 2001, Methods.
[37] S. Henikoff,et al. Amino acid substitution matrices from protein blocks. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[38] P S Kim,et al. Mechanisms of viral membrane fusion and its inhibition. , 2001, Annual review of biochemistry.
[39] P. Iversen,et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections , 2010, Nature Medicine.
[40] A. Sanchez,et al. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[41] H. Tompa. Polymer solutions , 1956 .
[42] Ming-Tsair Wey,et al. Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors , 2008, Antiviral Research.
[43] Stephan Günther,et al. Emergence of Zaire Ebola virus disease in Guinea. , 2014, The New England journal of medicine.
[44] R. L. Baldwin,et al. Comparison of NH exchange and circular dichroism as techniques for measuring the parameters of the helix-coil transition in peptides. , 1997, Biochemistry.
[45] K. Chandran,et al. Designed protein mimics of the Ebola virus glycoprotein GP2 α-helical bundle: Stability and pH effects , 2011, Protein science : a publication of the Protein Society.
[46] H. Edelhoch,et al. Spectroscopic determination of tryptophan and tyrosine in proteins. , 1967, Biochemistry.
[47] Gennaro Ciliberto,et al. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[48] P. S. Kim,et al. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[49] Joshua C. Johnson,et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study , 2010, The Lancet.
[50] Helena Berglund,et al. Improved solubility of TEV protease by directed evolution. , 2006, Journal of biotechnology.
[51] Kathryn L. Schornberg,et al. Role of Endosomal Cathepsins in Entry Mediated by the Ebola Virus Glycoprotein , 2006, Journal of Virology.
[52] X. Qiu,et al. Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies , 2012, Science Translational Medicine.
[53] Brett D. Welch,et al. Steric Accessibility of the HIV-1 gp41 N-trimer Region* , 2005, Journal of Biological Chemistry.
[54] Randy J. Read,et al. Acta Crystallographica Section D Biological , 2003 .
[55] S. Harrison,et al. Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.
[56] Kathryn L. Schornberg,et al. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. , 2008, Critical reviews in biochemistry and molecular biology.
[57] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[58] Michael S. Kay,et al. Potent D-peptide inhibitors of HIV-1 entry , 2007, Proceedings of the National Academy of Sciences.
[59] C. Hill,et al. Design of a Potent d-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to Resistance , 2010, Journal of Virology.
[60] William J. Salerno,et al. MONSTER: inferring non-covalent interactions in macromolecular structures from atomic coordinate data , 2004, Nucleic Acids Res..
[61] A. Sanchez,et al. Covalent Modifications of the Ebola Virus Glycoprotein , 2002, Journal of Virology.
[62] R. Lamb,et al. A core trimer of the paramyxovirus fusion protein: parallels to influenza virus hemagglutinin and HIV-1 gp41. , 1998, Virology.
[63] T J Cieslak,et al. Biological warfare : A historical perspective , 1997 .
[64] Majidat A. Muhammad,et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease , 2012, Proceedings of the National Academy of Sciences.
[65] H. Feldmann,et al. Proteolytic processing of Marburg virus glycoprotein. , 2000, Virology.
[66] D. Schwarzer,et al. Chemoselective ligation and modification strategies for peptides and proteins. , 2008, Angewandte Chemie.
[67] D. Littman,et al. Packaging system for rapid production of murine leukemia virus vectors with variable tropism , 1992, Journal of virology.
[68] Matthew T. Weinstock,et al. Synthesis and folding of a mirror-image enzyme reveals ambidextrous chaperone activity , 2014, Proceedings of the National Academy of Sciences.
[69] James L Cole,et al. Analysis of heterogeneous interactions. , 2004, Methods in enzymology.
[70] Shinji Watanabe,et al. Functional Importance of the Coiled-Coil of the Ebola Virus Glycoprotein , 2000, Journal of Virology.
[71] P. S. Kim,et al. Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues. , 1998, Journal of molecular biology.
[72] Claire Marie Filone,et al. Filoviruses Require Endosomal Cysteine Proteases for Entry but Exhibit Distinct Protease Preferences , 2012, Journal of Virology.
[73] K. Chandran,et al. C-peptide inhibitors of Ebola virus glycoprotein-mediated cell entry: effects of conjugation to cholesterol and side chain-side chain crosslinking. , 2013, Bioorganic & medicinal chemistry letters.